Your browser is no longer supported. Please, upgrade your browser.
IMMU Immunomedics, Inc. daily Stock Chart
IMMU [NASD]
Immunomedics, Inc.
Index- P/E- EPS (ttm)-1.82 Insider Own0.10% Shs Outstand213.25M Perf Week10.07%
Market Cap9.38B Forward P/E- EPS next Y-1.00 Insider Trans- Shs Float204.55M Perf Month26.05%
Income-362.90M PEG- EPS next Q-0.33 Inst Own78.80% Short Float14.39% Perf Quarter110.39%
Sales0.30M P/S31268.22 EPS this Y-120.60% Inst Trans3.31% Short Ratio6.66 Perf Half Y105.88%
Book/sh0.87 P/B47.49 EPS next Y30.10% ROA-67.40% Target Price41.60 Perf Year192.01%
Cash/sh2.38 P/C17.35 EPS next 5Y64.80% ROE-244.30% 52W Range8.80 - 42.69 Perf YTD95.27%
Dividend- P/FCF- EPS past 5Y-29.10% ROI-118.00% 52W High-3.21% Beta3.42
Dividend %- Quick Ratio8.40 Sales past 5Y-44.60% Gross Margin- 52W Low369.55% ATR1.76
Employees366 Current Ratio8.40 Sales Q/Q- Oper. Margin- RSI (14)70.70 Volatility3.92% 4.73%
OptionableYes Debt/Eq0.00 EPS Q/Q4.60% Profit Margin- Rel Volume0.41 Prev Close42.30
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume4.42M Price41.32
Recom1.90 SMA2015.24% SMA5021.79% SMA20090.98% Volume1,791,370 Change-2.32%
May-05-20Initiated Barclays Overweight $40
Apr-24-20Upgrade Goldman Sell → Neutral $5 → $22
Apr-23-20Reiterated H.C. Wainwright Buy $34 → $60
Apr-06-20Upgrade Wells Fargo Equal Weight → Overweight $34
Apr-03-20Downgrade Goldman Buy → Sell $24 → $5
Dec-27-19Reiterated H.C. Wainwright Buy $26 → $31
Dec-20-19Initiated BofA/Merrill Buy $26
Aug-08-19Reiterated H.C. Wainwright Buy $28 → $26
Mar-27-19Initiated Berenberg Buy $40
Mar-04-19Initiated H.C. Wainwright Buy $28
Jan-18-19Downgrade Wells Fargo Outperform → Market Perform
Nov-08-18Resumed Jefferies Buy
Nov-05-18Initiated Morgan Stanley Overweight
Oct-19-18Initiated Piper Jaffray Overweight
Sep-17-18Initiated Goldman Buy $36
Jun-07-18Initiated B. Riley FBR, Inc. Buy $53
May-05-17Upgrade Wells Fargo Market Perform → Outperform
Oct-06-16Resumed Jefferies Buy
Jun-21-16Downgrade Wells Fargo Outperform → Market Perform
May-06-16Upgrade Jefferies Hold → Buy
Jul-09-20 03:55PM  
Jul-08-20 11:29AM  
Jul-07-20 11:30AM  
10:22AM  
08:17AM  
Jul-06-20 10:54AM  
10:36AM  
07:55AM  
06:49AM  
Jul-02-20 04:05PM  
Jun-29-20 04:25PM  
Jun-24-20 06:01PM  
Jun-19-20 11:30AM  
Jun-08-20 04:15PM  
Jun-05-20 05:33PM  
11:31AM  
Jun-03-20 11:30AM  
Jun-02-20 06:34PM  
May-28-20 08:24AM  
08:00AM  
May-27-20 04:00PM  
May-20-20 01:30PM  
May-18-20 11:30AM  
May-13-20 05:01PM  
12:16AM  
May-12-20 08:19AM  
08:13AM  
May-07-20 11:21AM  
09:39AM  
09:01AM  
08:00AM  
May-06-20 04:00PM  
May-05-20 10:45AM  
May-04-20 08:00AM  
May-02-20 05:56PM  
May-01-20 04:05PM  
Apr-30-20 12:16PM  
08:00AM  
Apr-28-20 11:50PM  
08:12AM  
Apr-27-20 04:01PM  
Apr-24-20 09:15PM  
08:30PM  
07:00AM  
Apr-23-20 04:09PM  
01:45PM  
01:33PM  
09:12AM  
08:00AM  
07:53AM  
02:13AM  
Apr-22-20 02:20PM  
11:47AM  
11:28AM  
Apr-20-20 09:36AM  
Apr-17-20 05:51PM  
Apr-08-20 11:36AM  
10:05AM  
Apr-07-20 10:34AM  
09:28AM  
08:00AM  
Apr-06-20 08:00AM  
07:50AM  
Apr-05-20 07:44PM  
Apr-03-20 05:00PM  
11:30AM  
10:34AM  
08:31AM  
Mar-28-20 11:30AM  
Mar-25-20 08:00AM  
Mar-18-20 10:53AM  
Feb-28-20 08:58AM  
Feb-27-20 04:10PM  
04:00PM  
Feb-25-20 08:00AM  
Feb-21-20 08:57AM  
Feb-20-20 08:00AM  
Feb-17-20 10:06AM  
08:46AM  
Feb-14-20 08:00AM  
Feb-07-20 09:44AM  
Feb-06-20 08:00AM  
Jan-20-20 02:18PM  
Jan-19-20 09:13AM  
Jan-14-20 07:32AM  
Dec-30-19 05:36AM  
Dec-27-19 01:47PM  
12:08PM  
10:02AM  
07:59AM  
Dec-26-19 08:00AM  
Dec-19-19 10:09AM  
Dec-14-19 07:30AM  
Dec-12-19 08:50AM  
Dec-10-19 02:30PM  
Dec-09-19 04:01PM  
Dec-08-19 07:27PM  
Dec-04-19 08:29PM  
10:41AM  
07:06AM  
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody; and a collaboration and license agreement with pH Pharma Co. Ltd. for the development and commercialization of multiple novel antibody-drug conjugates in oncology. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Avoro Capital Advisors LLCDirectorMay 01Buy28.501,750,00049,875,00026,250,000May 01 10:20 AM
Avoro Capital Advisors LLCDirectorDec 05Buy17.502,000,00035,000,00024,500,000Dec 09 04:05 PM
BALL BRYANChief Quality OfficerOct 03Buy14.185,00070,89710,000Oct 03 05:30 PM
Avoro Capital Advisors LLCDirectorOct 03Buy14.10500,0007,050,00022,500,000Oct 04 09:50 AM
Avoro Capital Advisors LLCDirectorOct 02Buy13.231,000,00013,230,00022,000,000Oct 04 09:50 AM